MAPT and Alzheimer disease: Higher correlation with biomarkers and cognitive measures results in more accuracy for p‐tau217 compared to other p‐tau epitopes; it has demonstrated a 3.3‐ to 3.9‐fold increase in AD, while p‐tau181 only has shown a 1.7‐fold increase.25, 56, 61